Categories: News

Biotage – Change in number of shares and votes

UPPSALA, Sweden, Oct. 29, 2021 /PRNewswire/ — As previously announced, Biotage AB (publ) (“Biotage“) has during October 2021 issued 781,991 new ordinary shares in connection with the acquisition of ATDBio Limited.
Prior to the issue, the total number of outstanding shares in Biotage amounted to 65,445,097 and the total number of votes amounted to 65,226,115.3. Through the issue the number of shares in Biotage has increased by 781,991 ordinary shares, corresponding to 781,991 votes. As of today, the last trading day of the month, the total number of registered and outstanding shares of Biotage amounts to 66,227,088, whereof 65,983,775 are ordinary shares and 243,313 are class C shares. As of today, the number of votes in Biotage amounts to 66,008,106.3, and the registered share capital amounts to SEK 92,055,652.32.

This information is information that Biotage AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 17.00 CET on 29 October 2021.

Contact persons:
Tomas Blomquist, CEO
Tel: 0705 23 01 63, tomas.blomquist@biotage.com

About Biotage
Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs approx. 485 people worldwide. The Group had sales of 1,092 MSEK in 2020 and our products are sold in more than 70 countries. Biotage’s share (BIOT) is listed in the Mid Cap segment on the NASDAQ Stockholm.
Website: www.biotage.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/biotage/r/biotage—change-in-number-of-shares-and-votes,c3441519

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/biotage—change-in-number-of-shares-and-votes-301412024.html

SOURCE Cision AB

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

8 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

8 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

1 day ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

1 day ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

1 day ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

1 day ago